Darunavir Amarox (Darunavir)
HIV Protease Inhibitor — Second-Generation Antiretroviral Agent
Quick Facts About Darunavir Amarox
Key Takeaways About Darunavir Amarox
- Requires a pharmacokinetic booster: Darunavir Amarox must always be co-administered with low-dose ritonavir or cobicistat to achieve therapeutic blood levels
- High genetic barrier to resistance: Darunavir retains activity against many HIV strains resistant to other protease inhibitors, making it a preferred choice in international guidelines
- Take with food: Darunavir absorption is significantly increased when taken with a meal — always take your tablets during or immediately after eating
- Sulfonamide moiety: Darunavir contains a sulfonamide group — use with caution if you have a known allergy to sulfa drugs
- Monitor liver function: Regular liver function tests are recommended, particularly in patients with underlying hepatitis B or C co-infection
What Is Darunavir Amarox and What Is It Used For?
Darunavir Amarox is an antiretroviral medication containing darunavir, a second-generation HIV protease inhibitor. It is used in combination with a pharmacokinetic enhancer (ritonavir or cobicistat) and other antiretroviral drugs to treat HIV-1 infection in adults, adolescents, and children aged 3 years and older weighing at least 15 kg.
Darunavir belongs to the class of medicines known as protease inhibitors (PIs). The HIV protease enzyme plays a critical role in the life cycle of the human immunodeficiency virus: once the virus has infected a human cell and produced new viral proteins, the protease enzyme cleaves these large polyprotein precursors (Gag and Gag-Pol) into smaller, functional proteins that are essential for assembling new, mature virus particles. By selectively and potently inhibiting this enzyme, darunavir prevents the formation of mature, infectious HIV virions. The result is a dramatic reduction in viral replication and, consequently, a decrease in the amount of HIV in the blood (viral load).
What distinguishes darunavir from earlier protease inhibitors — such as lopinavir, atazanavir, or saquinavir — is its unique molecular structure that allows it to form very strong hydrogen bonds with the protease enzyme. This tight binding means that the virus must accumulate multiple resistance mutations simultaneously before darunavir loses its effectiveness, a property known as a high genetic barrier to resistance. In clinical trials, treatment-naive patients on darunavir-based regimens have shown sustained virological suppression rates exceeding 80% at 48 weeks, with very low rates of treatment-emergent resistance.
Darunavir, like other protease inhibitors, requires pharmacokinetic boosting to achieve adequate plasma concentrations. When taken alone, darunavir is extensively metabolized by the liver enzyme CYP3A4, resulting in blood levels that are too low to suppress HIV effectively. Co-administration with a low dose of ritonavir (100 mg) or cobicistat (150 mg) inhibits this metabolic pathway and raises darunavir concentrations to therapeutic levels. The choice between ritonavir and cobicistat as a booster depends on the individual patient’s other medications, tolerability, and clinical situation.
The Darunavir Amarox 400 mg film-coated tablet formulation is designed for flexible dosing. In treatment-naive patients or treatment-experienced patients without darunavir resistance-associated mutations, the recommended regimen is 800 mg (two 400 mg tablets) once daily with ritonavir 100 mg or cobicistat 150 mg, taken with food. For treatment-experienced patients with one or more darunavir resistance-associated mutations, the regimen is 600 mg (one and a half 400 mg tablets, or alternative strength tablets) twice daily with ritonavir 100 mg twice daily. Your doctor will determine the appropriate regimen based on your resistance testing results and treatment history.
Modern HIV treatment uses a combination approach called antiretroviral therapy (ART), which typically includes three or more drugs from at least two different classes. Darunavir is used as the protease inhibitor component of ART, always in combination with a pharmacokinetic booster and a backbone of other antiretroviral agents (usually two nucleoside reverse transcriptase inhibitors such as tenofovir/emtricitabine or abacavir/lamivudine). The DHHS and EACS guidelines recommend boosted darunavir as a preferred or alternative protease inhibitor in multiple clinical scenarios.
What Should You Know Before Taking Darunavir Amarox?
Before starting Darunavir Amarox, your doctor must evaluate your liver function, assess for sulfa allergy, review your current medications for interactions, and in treatment-experienced patients, perform resistance testing to confirm susceptibility to darunavir.
Contraindications
There are several situations in which Darunavir Amarox must not be used. These absolute contraindications exist because the combination of darunavir with certain conditions or medications poses an unacceptable risk of serious harm.
Do not take Darunavir Amarox if you:
- Are allergic to darunavir or any of the other ingredients in the film-coated tablet
- Have severe liver impairment (Child-Pugh Class C) — your doctor will evaluate liver function with blood tests before starting treatment
- Are currently taking any of the following contraindicated medications:
- Rifampin (used for tuberculosis) — dramatically reduces darunavir levels, leading to potential virological failure and resistance development
- Simvastatin or lovastatin (cholesterol-lowering statins) — risk of severe muscle damage including rhabdomyolysis
- Oral midazolam or triazolam (sedatives) — risk of prolonged or excessive sedation and respiratory depression
- Ergot derivatives (ergotamine, dihydroergotamine, methylergonovine) — risk of ergotism with peripheral vasospasm and ischemia
- Pimozide or lurasidone (antipsychotics) — risk of cardiac arrhythmias due to elevated drug levels
- Cisapride (gastrointestinal agent) — risk of cardiac arrhythmias
- Sildenafil (when used for pulmonary arterial hypertension) — risk of dangerous hypotension
- Alfuzosin (for benign prostatic hyperplasia) — risk of severe hypotension
- Elbasvir/grazoprevir (hepatitis C antivirals) — risk of elevated ALT levels
- Lopinavir/ritonavir (another HIV PI combination) — unfavorable pharmacokinetic interaction; must not be combined
- Are taking products containing St. John’s Wort (Hypericum perforatum), as this herbal supplement significantly reduces darunavir blood levels and may lead to virological failure and resistance
Warnings and Precautions
Even when Darunavir Amarox is not contraindicated, there are several important warnings that require careful monitoring during treatment. Discuss all of the following with your healthcare provider before starting this medication.
Drug-induced hepatitis has been reported in patients receiving darunavir. Patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk of developing liver function abnormalities including potentially severe and life-threatening hepatic events. Liver function tests must be performed before initiating therapy and should be monitored at regular intervals during treatment. Seek immediate medical attention if you develop signs of liver problems: fever, malaise, nausea, vomiting, jaundice (yellowing of skin and eyes), dark urine, pale stools, right upper abdominal pain, or unexplained fatigue.
During post-marketing surveillance, severe skin reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have been reported, some of which were accompanied by fever and/or elevated liver enzymes. Darunavir contains a sulfonamide moiety. In patients with a known sulfonamide allergy, there is a theoretical cross-reactivity risk, although clinical data on this are limited. Discontinue darunavir immediately and seek emergency medical care if you develop a severe rash, especially if accompanied by blistering, peeling skin, mucosal involvement, fever, or systemic symptoms.
Tell your doctor if you have any of the following conditions:
- Hemophilia type A or B: Increased bleeding events, including spontaneous skin hematomas and hemarthroses, have been reported in patients with hemophilia receiving protease inhibitors. Additional factor VIII may be required.
- Diabetes mellitus: New-onset or worsening diabetes, hyperglycemia, and diabetic ketoacidosis have been reported in patients taking protease inhibitors. Blood glucose monitoring may need to be more frequent, and adjustments to antidiabetic medications may be necessary.
- Pre-existing liver disease: Even mild hepatic impairment warrants more frequent monitoring of liver function tests during darunavir therapy.
- Hepatitis B or C co-infection: Significantly increases the risk of hepatotoxicity. Your doctor will monitor liver enzymes more closely.
- Known sulfonamide allergy: While the clinical significance of cross-reactivity between darunavir and other sulfonamides is not established, inform your doctor about any history of sulfa allergy.
Skin rash: Rash (all grades, all causality) occurred in approximately 10.3% of subjects treated with darunavir/ritonavir in clinical trials. The rash was generally mild to moderate and often resolved with continued therapy. However, if you develop a progressive rash or a rash accompanied by systemic symptoms, contact your doctor promptly.
Immune reconstitution inflammatory syndrome (IRIS): When effective antiretroviral therapy is started, the recovering immune system may produce an inflammatory response to residual opportunistic infections such as Mycobacterium avium complex, cytomegalovirus retinitis, Pneumocystis jirovecii pneumonia, or tuberculosis. This can cause a temporary worsening of symptoms and may occur within the first few weeks to months of starting treatment. Additionally, autoimmune disorders (such as Graves’ disease, autoimmune hepatitis, polymyositis, or Guillain-Barré syndrome) have been reported to occur in the setting of immune reconstitution, sometimes many months after initiation of ART.
Fat redistribution: Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy). This may include loss of fat from the face, arms, and legs (lipoatrophy) and accumulation of fat in the abdomen, breasts, and back of the neck (“buffalo hump”). The long-term health consequences of these changes are not yet fully understood. Regular physical examination and metabolic monitoring are recommended.
Osteonecrosis: Cases of osteonecrosis (death of bone tissue) have been reported in patients on combination antiretroviral therapy, particularly in those with advanced HIV disease, long-term exposure to ART, corticosteroid use, alcohol consumption, severe immunosuppression, and higher body mass index. Symptoms include joint stiffness and pain, particularly in the hips, knees, and shoulders. If you experience unexplained joint pain, contact your healthcare provider.
Pregnancy and Breastfeeding
Darunavir may be used during pregnancy when the potential benefit justifies the potential risk. Data from the Antiretroviral Pregnancy Registry and published literature indicate that darunavir/ritonavir use during pregnancy does not significantly increase the risk of major birth defects compared to the background rate. However, pharmacokinetic studies have demonstrated that darunavir plasma concentrations may be reduced during the second and third trimesters of pregnancy, potentially requiring dosage adjustments. Your obstetrician and HIV specialist will work together to determine the optimal treatment regimen during pregnancy.
Breastfeeding is not recommended for women living with HIV, regardless of whether they are on antiretroviral treatment, because HIV can be transmitted to the infant through breast milk. Additionally, darunavir is excreted into human breast milk. If you are currently breastfeeding or considering doing so, discuss alternative infant feeding options with your healthcare provider.
Darunavir co-administered with ritonavir may reduce the effectiveness of combined hormonal contraceptives (ethinyl estradiol-containing pills, patches, or rings). Women of childbearing potential should use a reliable barrier method of contraception (such as condoms) or switch to a non-hormonal method in addition to or instead of hormonal contraceptives. When cobicistat is used as the booster, alternative contraceptive methods containing at least 30 mcg ethinyl estradiol may be considered — discuss with your doctor.
Elderly Patients
Clinical experience with darunavir in patients aged 65 years and older is limited. Elderly patients are more likely to have decreased hepatic and renal function, and may be taking multiple concomitant medications that increase the risk of drug interactions. If you are in this age group, your doctor will exercise particular caution and may monitor your treatment more closely. No specific dose adjustment is recommended solely based on age, but individual assessment is essential.
Children and Adolescents
Darunavir is approved for use in children aged 3 years and older weighing at least 15 kg. The 400 mg film-coated tablet formulation is suitable for children and adolescents who can swallow tablets and whose weight-based dosing corresponds to the available tablet strengths. For younger children or those unable to swallow tablets, an oral suspension formulation of darunavir is available. Dosing in pediatric patients is based on body weight, and your child’s doctor will determine the appropriate dose.
How Does Darunavir Amarox Interact with Other Drugs?
Darunavir has significant interactions with many medications because it is metabolized by CYP3A4 and also acts as an inhibitor of CYP3A4 and CYP2D6. When boosted with ritonavir or cobicistat, these interactions are amplified. Some combinations are strictly contraindicated, while others require dose adjustments or enhanced monitoring.
Drug interactions are one of the most critical aspects of darunavir therapy. Because darunavir is both a substrate and an inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme, co-administration with other drugs that are metabolized by, induce, or inhibit CYP3A4 may result in altered plasma concentrations of darunavir and/or the co-administered drug. The pharmacokinetic booster (ritonavir or cobicistat) further complicates the interaction profile, as both are potent CYP3A4 inhibitors. Additionally, darunavir has weak inhibitory effects on CYP2D6. Before starting darunavir, always provide your physician and pharmacist with a complete list of all medications you are taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins.
Major Contraindicated Interactions
| Drug / Class | Interaction Type | Clinical Consequence |
|---|---|---|
| Rifampin (anti-tuberculosis) | Contraindicated | Reduces darunavir levels by approximately 40%, leading to virological failure and resistance |
| Simvastatin, Lovastatin | Contraindicated | Greatly increased statin levels; risk of rhabdomyolysis (severe muscle breakdown) |
| Oral Midazolam, Triazolam | Contraindicated | Risk of prolonged or excessive sedation and respiratory depression |
| Ergot derivatives (ergotamine, dihydroergotamine) | Contraindicated | Risk of acute ergot toxicity including peripheral vasospasm and ischemia |
| Pimozide, Lurasidone | Contraindicated | Increased drug levels; risk of QT prolongation and cardiac arrhythmias |
| Sildenafil (for pulmonary arterial hypertension) | Contraindicated | Risk of severe and potentially fatal hypotension, visual disturbances, priapism |
| St. John’s Wort (Hypericum perforatum) | Contraindicated | Significantly reduces darunavir levels; may lead to virological failure and resistance |
| Lopinavir/ritonavir | Contraindicated | Significantly reduced darunavir concentrations; must not be combined |
| Elbasvir/grazoprevir (Hepatitis C) | Contraindicated | Increased risk of ALT elevations and hepatotoxicity |
Interactions Requiring Dose Adjustment or Monitoring
| Drug / Class | Effect | Recommendation |
|---|---|---|
| Rifabutin (anti-tuberculosis) | Increased rifabutin levels | Reduce rifabutin dose to 150 mg every other day; monitor for neutropenia |
| Atorvastatin, Pravastatin, Rosuvastatin | Increased statin levels | Start with lowest dose; do not exceed atorvastatin 20 mg/day; monitor for myopathy |
| Carbamazepine, Phenobarbital, Phenytoin | Decreased darunavir levels; altered anticonvulsant levels | Monitor anticonvulsant levels; consider alternative agents; use with caution |
| Hormonal contraceptives (ethinyl estradiol) | Reduced ethinyl estradiol/norethindrone levels | Use alternative or additional barrier contraception |
| Methadone | Decreased methadone levels | Monitor for opioid withdrawal symptoms; dose adjustment may be needed |
| Sildenafil, Tadalafil, Vardenafil (for erectile dysfunction) | Increased PDE5 inhibitor levels | Use lowest effective dose with increased monitoring interval (sildenafil max 25 mg/48h) |
| Clarithromycin | Increased clarithromycin levels | Reduce clarithromycin dose by 50% if CrCl 30–60 mL/min; by 75% if CrCl <30 mL/min |
| Warfarin | Altered warfarin levels | Monitor INR closely when initiating or stopping darunavir |
| Cyclosporine, Tacrolimus, Sirolimus | Significantly increased immunosuppressant levels | Therapeutic drug monitoring required; dose reduction typically necessary |
Interactions with Other HIV Medications
- Lopinavir/ritonavir: Co-administration is contraindicated — the combination results in significantly decreased darunavir concentrations
- Efavirenz, Nevirapine (NNRTIs): May decrease darunavir trough levels. When used with efavirenz, darunavir must be dosed at 600 mg twice daily with ritonavir 100 mg twice daily, regardless of treatment history
- Etravirine (NNRTI): Can be used in combination with darunavir/ritonavir 600/100 mg twice daily without dose adjustments
- Tenofovir disoproxil fumarate: Tenofovir levels may increase when co-administered with darunavir/ritonavir; monitor renal function
- Maraviroc: Reduce maraviroc dose to 150 mg twice daily when co-administered with darunavir/ritonavir
- Dolutegravir, Raltegravir (integrase inhibitors): No clinically significant interactions expected; no dose adjustment required
What Is the Correct Dosage of Darunavir Amarox?
The dosage of Darunavir Amarox depends on the patient’s treatment history, resistance profile, and age/weight. It must always be taken with a pharmacokinetic enhancer (ritonavir or cobicistat) and with food. Never adjust your dose without consulting your doctor.
Darunavir Amarox must always be taken in combination with a pharmacokinetic enhancer and with food. Food increases darunavir bioavailability and ensures adequate drug absorption. The type of food does not significantly affect absorption — any meal is sufficient. The tablets should be swallowed whole with water and must not be crushed or chewed.
Adults — Treatment-Naive or Treatment-Experienced Without Darunavir Resistance Mutations
Once-Daily Regimen
Darunavir 800 mg (two 400 mg tablets) once daily
Plus ritonavir 100 mg once daily OR cobicistat 150 mg once daily
Taken with food, at the same time each day. This is the preferred regimen for treatment-naive patients and treatment-experienced patients whose genotypic resistance testing shows no darunavir resistance-associated mutations (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V).
Adults — Treatment-Experienced with Darunavir Resistance Mutations
Twice-Daily Regimen
Darunavir 600 mg twice daily (using appropriate tablet combinations)
Plus ritonavir 100 mg twice daily
Taken with food, approximately 12 hours apart. This regimen is indicated for treatment-experienced patients with one or more darunavir resistance-associated mutations. Note: cobicistat cannot be used as the booster for twice-daily darunavir dosing.
Children and Adolescents (Aged 3 Years and Older, Weight ≥15 kg)
Weight-Based Dosing
Pediatric dosing is based on body weight. The following table summarizes the dosing for the film-coated tablets:
| Body Weight | Darunavir Dose | Ritonavir Dose |
|---|---|---|
| 15 to <30 kg | 600 mg once daily | 100 mg once daily |
| 30 to <40 kg | 675 mg once daily | 100 mg once daily |
| ≥40 kg | 800 mg once daily | 100 mg once daily |
For treatment-experienced pediatric patients with darunavir resistance mutations, twice-daily dosing is used with weight-based dose adjustments determined by the treating physician. An oral suspension formulation is available for children who cannot swallow tablets.
Elderly
There is limited data on the use of darunavir in patients over 65 years of age. No specific dose adjustment is recommended based on age alone, but caution is advised due to the greater frequency of decreased hepatic and renal function, concomitant disease, and other drug therapy in the elderly population. Individual assessment and closer monitoring are recommended.
Missed Dose
Once-daily dosing: If you miss a dose by less than 12 hours, take the missed dose with food as soon as you remember, and then take the next dose at the regular time. If you miss a dose by more than 12 hours, skip the missed dose entirely and take the next dose at the regular time. Do not take a double dose to make up for the missed one.
Twice-daily dosing: If you miss a dose by less than 6 hours, take the missed dose with food as soon as you remember, and then take the next dose at the regular time. If you miss a dose by more than 6 hours, skip the missed dose and take the next dose at the regular time. Do not take a double dose.
It is very important not to stop taking darunavir without consulting your doctor first. Stopping treatment or missing doses frequently can allow the virus to replicate and develop resistance, which may make darunavir and other HIV medications less effective or ineffective.
Overdose
There is no specific antidote for darunavir overdose. In the event of an overdose, general supportive measures should be employed, including monitoring of vital signs, clinical status, and standard medical interventions as appropriate. Since darunavir is highly protein-bound, dialysis is unlikely to be effective in significantly removing the drug from the blood. If you suspect an overdose, contact your healthcare provider, local poison control center, or emergency services immediately.
What Are the Side Effects of Darunavir Amarox?
Like all medicines, Darunavir Amarox can cause side effects, although not everybody gets them. The most commonly reported side effects are diarrhea, nausea, rash, headache, and abdominal pain. Serious but rare side effects include hepatotoxicity, severe skin reactions, and new-onset diabetes.
The side effect profile of darunavir has been well characterized through extensive clinical trials involving thousands of patients and through ongoing post-marketing surveillance. Most side effects are mild to moderate in severity and often diminish with continued therapy. However, some adverse reactions can be serious and require immediate medical attention. Always report any unusual symptoms to your healthcare provider, particularly during the first weeks of treatment.
It is important to distinguish between side effects caused by darunavir itself and those related to the pharmacokinetic booster (ritonavir or cobicistat) or other components of your antiretroviral regimen. Your doctor will help you identify which drug is most likely causing a particular side effect and determine the best course of action.
Very Common (may affect more than 1 in 10 people)
- Diarrhea
- Nausea
Common (may affect up to 1 in 10 people)
- Headache
- Abdominal pain and distension
- Vomiting
- Flatulence (gas)
- Dyspepsia (indigestion)
- Rash (including maculopapular, macular, eczema)
- Pruritus (itching)
- Fatigue and asthenia (weakness)
- Insomnia (difficulty sleeping)
- Dizziness
- Peripheral neuropathy (tingling, numbness in hands/feet)
- Elevated liver enzymes (ALT, AST)
- Elevated blood lipids (cholesterol, triglycerides)
- Elevated blood glucose (hyperglycemia)
- Elevated pancreatic amylase
- Decreased white blood cell count
Uncommon (may affect up to 1 in 100 people)
- Angioedema (swelling of face, lips, tongue)
- Urticaria (hives)
- Drug hypersensitivity
- Acute pancreatitis
- Hepatitis (liver inflammation)
- Acute hepatic failure
- Myalgia (muscle pain)
- Arthralgia (joint pain)
- Osteonecrosis (bone tissue death)
- Renal insufficiency
- Nephrolithiasis (kidney stones)
- Gynecomastia (breast enlargement in men)
- Fat redistribution (lipodystrophy)
- Depression
- Abnormal dreams
Rare (may affect up to 1 in 1,000 people)
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- Erythema multiforme
- Acute generalized exanthematous pustulosis (AGEP)
- Drug rash with eosinophilia and systemic symptoms (DRESS)
- Diabetes mellitus (new onset)
- Diabetic ketoacidosis
- Rhabdomyolysis
Contact your doctor or seek emergency care immediately if you experience any of the following: severe skin rash with blistering or peeling, especially if accompanied by fever or mucosal ulcers (mouth, eyes, genitals); signs of liver problems including yellowing of the skin or eyes, dark urine, severe nausea and vomiting, or right-sided abdominal pain; signs of severe allergic reaction including swelling of face, throat, or tongue, difficulty breathing, or rapid heartbeat; severe and persistent abdominal pain that may indicate pancreatitis.
Metabolic effects: Protease inhibitors, including darunavir, have been associated with metabolic abnormalities including elevated cholesterol and triglyceride levels, insulin resistance, and hyperglycemia. These metabolic changes may increase the long-term risk of cardiovascular disease. Your doctor will monitor your lipid profile and blood glucose regularly and may recommend lifestyle modifications (diet, exercise) or prescribe lipid-lowering medications if necessary. When selecting a statin, avoid simvastatin and lovastatin (contraindicated); atorvastatin, pravastatin, or rosuvastatin may be used with dose limitations and monitoring.
How Should You Store Darunavir Amarox?
Darunavir Amarox film-coated tablets should be stored at room temperature below 30°C in the original packaging to protect from moisture. Keep out of reach and sight of children. Do not use after the expiry date.
Proper storage of medications is essential to ensure they remain effective and safe to use. Darunavir Amarox 400 mg film-coated tablets should be stored at a temperature below 30 degrees Celsius (86 degrees Fahrenheit). Keep the tablets in the original blister packaging or bottle to protect them from moisture. Do not transfer the tablets to a different container unless advised by your pharmacist.
Do not use Darunavir Amarox after the expiry date which is stated on the carton and blister/bottle after “EXP”. The expiry date refers to the last day of that month. Do not store in the bathroom or other areas with high humidity, as moisture can degrade the medication. Keep the medication away from direct sunlight and heat sources.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment and prevent accidental exposure.
If you travel with your medication, keep it in your carry-on luggage in its original packaging with the pharmacy label visible. Ensure you carry sufficient supply for your trip plus additional days in case of travel delays. In hot climates, avoid leaving the medication in a car or in direct sunlight.
What Does Darunavir Amarox Contain?
Each film-coated tablet contains 400 mg of darunavir (as darunavir ethanolate) as the active substance, along with inactive ingredients that form the tablet core and film coating.
The active substance is darunavir. Each film-coated tablet contains 400 mg of darunavir (present as darunavir ethanolate). Darunavir ethanolate is a solvate form of darunavir used to improve the pharmaceutical properties of the formulation.
Tablet core excipients (inactive ingredients that give the tablet its structure):
- Colloidal anhydrous silica (flow agent)
- Microcrystalline cellulose (filler and binder)
- Crospovidone (disintegrant — helps the tablet break apart in the stomach)
- Magnesium stearate (lubricant)
- Hypromellose (binder)
Film coating (the outer layer that makes the tablet easier to swallow and protects the active substance):
- Polyvinyl alcohol (film former)
- Titanium dioxide (E171) (colorant)
- Macrogol/PEG (plasticizer)
- Talc (anti-adherent)
- Iron oxide red (E172) (colorant, if applicable)
Darunavir Amarox 400 mg tablets are typically oval or oblong shaped, with markings for identification purposes. The exact appearance may vary by manufacturer batch. Always verify that the tablets you receive match the description on the patient information leaflet provided with your medication.
Important note about excipients: If you have a known allergy or intolerance to any of the inactive ingredients listed above, inform your doctor or pharmacist before taking this medication. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should consult their doctor before taking any medicine (this applies if the formulation contains lactose; check the specific patient information leaflet with your tablets).
Frequently Asked Questions About Darunavir Amarox
Darunavir Amarox is a generic formulation of darunavir, containing the same active substance (darunavir ethanolate) at the same strength (400 mg per tablet) as the originator product and other authorized generic versions. Generic medicines undergo rigorous regulatory review to demonstrate bioequivalence — meaning they are absorbed into the body at the same rate and to the same extent as the reference product. Therefore, Darunavir Amarox is expected to have the same efficacy, safety, and tolerability as other darunavir formulations. The main differences may relate to inactive ingredients (excipients), tablet appearance, and price.
Yes, switching between bioequivalent darunavir formulations is generally considered safe and effective. However, any change in your antiretroviral regimen should be done in consultation with your HIV specialist. Your doctor may schedule a follow-up viral load test after the switch to confirm continued virological suppression. If you notice any new or unexpected side effects after switching, report them to your healthcare provider promptly.
Yes, darunavir must always be taken with food. Pharmacokinetic studies have shown that food significantly increases the bioavailability of darunavir — the amount of drug that reaches your bloodstream. Taking darunavir without food results in lower plasma concentrations that may be insufficient for viral suppression, potentially leading to treatment failure and resistance. The type of food does not matter; any meal or substantial snack is sufficient. Simply take your tablets during or immediately after eating.
There is no absolute contraindication to consuming alcohol while taking darunavir, but caution is strongly advised. Both alcohol and darunavir are metabolized by the liver, and concurrent use may place additional strain on hepatic function. This is particularly concerning for patients with hepatitis B or C co-infection or any pre-existing liver condition. Excessive alcohol consumption can also impair medication adherence, which is critical for maintaining viral suppression. Discuss your alcohol consumption honestly with your healthcare provider.
HIV treatment is currently a lifelong commitment. While antiretroviral therapy, including darunavir, can suppress the virus to undetectable levels (meaning it cannot be transmitted sexually — the “Undetectable = Untransmittable” or U=U principle), it does not cure HIV. If you stop taking your medication, the virus will rebound, potentially develop resistance, and your immune system will begin to deteriorate. Your healthcare team will monitor your treatment regularly through viral load and CD4 cell count tests. Never stop or change your HIV medications without discussing it with your doctor first.
Mild to moderate rash is relatively common with darunavir and often resolves with continued treatment. However, if your rash is severe, spreading rapidly, or accompanied by blistering, peeling, mucosal ulcers (in the mouth, eyes, or genitals), fever, malaise, muscle aches, joint pain, or elevated liver enzymes, seek immediate medical attention. These symptoms may indicate a serious skin reaction such as Stevens-Johnson syndrome or DRESS, which require urgent evaluation and potential discontinuation of the medication.
References
This article is based on evidence from international peer-reviewed medical literature, regulatory authority assessments, and clinical practice guidelines. All sources used are listed below.
- European Medicines Agency (EMA). Summary of Product Characteristics: Darunavir film-coated tablets. Last updated 2025. Available from: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Prescribing Information: Prezista (darunavir). Janssen Therapeutics. Reference ID: 5057866. Available from: www.accessdata.fda.gov
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services (DHHS). Updated 2025. Available from: clinicalinfo.hiv.gov
- European AIDS Clinical Society (EACS). Guidelines Version 12.0, October 2023. Available from: www.eacsociety.org
- World Health Organization (WHO). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. Available from: www.who.int
- Orkin C, et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive adults with HIV-1: subgroup analyses of the AMBER study. HIV Medicine. 2020;21(10):651–660. doi:10.1111/hiv.12961
- Clotet B, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2. The Lancet. 2007;369(9568):1169–1178. doi:10.1016/S0140-6736(07)60497-8
- De Meyer S, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Research and Human Retroviruses. 2008;24(3):379–388. doi:10.1089/aid.2007.0203
- British National Formulary (BNF). Darunavir. NICE. Available from: bnf.nice.org.uk
- Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report. Updated semiannually. Available from: www.apregistry.com
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specializations in infectious diseases, clinical pharmacology, and HIV medicine. Our team follows the GRADE evidence framework and adheres to international guidelines from WHO, EMA, FDA, DHHS, EACS, and BHIVA to ensure the highest standard of medical accuracy.
All clinical claims are graded using the GRADE framework. This article primarily references Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) and regulatory authority assessments (EMA, FDA). Where lower-level evidence is used, this is clearly noted.
iMedic receives no funding from pharmaceutical companies, medical device manufacturers, or healthcare organizations. All content is independently produced. Our editorial team has no conflicts of interest related to the medications or treatments discussed. See our Editorial Standards for full details.
Last medical review: by iMedic Medical Review Board.
Next scheduled review: .
Found an error or have a suggestion? Contact our editorial team.